Comprehensive genomic profiling for homologous recombination deficiency guides PARP inhibitor therapy recommendations in ovarian cancer

Key Points

• Homologous recombination deficiency significantly predicts the effectiveness of PARP inhibitor therapy.
• In this analysis, patients with homologous recombination deficiency demonstrated improved outcomes with PARP inhibitors.
• Assessment of genomic profiling data was conducted to tailor therapy recommendations for ovarian cancer patients.
• Genomic profiling may enhance precision medicine strategies in cancer treatment, advocating for broader use in clinical settings.